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A B S T R A C T
Background: Among visitors to the (sub)tropics, 20–50% contract travellers' diarrhoea (TD) and 5–30% take
antibiotics. While shortening the duration of illness, antimicrobials predispose to acquisition of multi-drug re-
sistant bacteria. Therefore, liberal use is no longer advocated. Although antibiotics kill pathogens, no data
support the view that they could prevent post-infectious sequelae. We investigated how antibiotic use for TD
abroad impacts the pathogen findings at return.
Materials and methods: We revisited 456 travellers' clinical data and stool pathogens examined by qPCR for
Salmonella, Yersinia, Campylobacter, Shigella, Vibrio cholerae and enteroaggregative (EAEC), enteropathogenic
(EPEC), enterotoxigenic (ETEC), enterohaemorrhagic (EHEC) and enteroinvasive (EIEC) Escherichia coli.
Results: Among travellers with TD, antibiotic users had pathogen-positive samples less frequently than non-users
(50% versus 83%). The difference was significant for EPEC (23% versus 47%) and EAEC (27% versus 54%), but
not ETEC (17% versus 26%) or the other pathogens. Shigella/EIEC was found more often among antibiotic users
than non-users (4% versus 1%).
Conclusion: Despite antibiotic treatment of TD, half of the users still had stool pathogens at return, reflecting
either antibiotic resistance of pathogens or recolonisation/reinfection while abroad. Treatment of TD with an-
tibiotics during travel should not be interpreted to indicate eradication of pathogens.
1. Introduction
Of the 80–100 million contracting travellers' diarrhoea (TD) an-
nually, 5–30% take antibiotics [1–11]. Antibiotic use for TD – a disease
which generally remains mild or moderate and resolves spontaneously
– has recently been debated, since ample studies show that anti-
microbials used during travel double the risk of becoming colonised by
intestinal multidrug-resistant bacteria, especially extended-spectrum
beta-lactamase-producing Enterobacteriaceae (ESBL-PE) [7,8,10–12].
Despite this risk, some guidelines [13] still recommend antibiotics as an
alternative even for non-severe cases. Besides shortening the duration
of TD, another justification for liberal use has been the presumed
potential of antibiotics, by rapidly killing pathogens, to prevent post-
infectious sequelae such as irritable bowel syndrome (IBS) [13].
TD is mostly caused by bacterial pathogens (50–80%) [13–16].
Numerous investigations suggest that although antibiotics are taken to
kill pathogens, eradication rates do not correlate with cure [17–22].
Indeed, pathogens are still found, although in reduced numbers, in stool
samples collected shortly after a course of antibiotics, completed while
abroad [17–22]. Many studies looking at samples collected from re-
turning travellers at home omit to specify whether antibiotics have
been used during travel or not [14,15]; only few report separately the
findings of those having taken antibiotics [23]. To obtain data on the
impact of antibiotic use on post-travel pathogen findings, we revisited a
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data set collected on 456 Finnish travellers and compared individual
results among those having taken versus not taken antimicrobials.
2. Methods
2.1. Study design and volunteers
The study was designed to assess how antibiotic use during travel
impacts the bacterial pathogen findings in stool samples taken at return.
We revisited our data on 526 Finnish travellers recruited 2009–2010
[16,24], selecting 456 who all had provided information on their use of
antibiotics and provided both pre- and post-travel stool samples
(Fig. 1).
The Ethics Committee of the Helsinki University Hospital approved
the study protocol. All volunteers had given written informed consent.
We have earlier reported stool pathogen findings among travellers
visiting various regions of the world [24] and among those without
antibiotic use [16,25] as well as the findings of resistant En-
terobacteriacae [7,26,27], and travel-related health problems [28].
2.2. Definitions and categorisation of travel destinations
TD was defined according to the World Health Organisation (WHO)
criteria for diarrhoea as loose/liquid stools three times per day or more
frequently than usual for the individual, as previously described [16].
Severe TD was defined as six or more loose/liquid stools per day, TD
accompanied by fever or overt blood in stools or TD requiring hospi-
talisation. Based on the presence or absence of symptoms at the time of
the post-travel sampling, those with TD were further categorised into
resolved TD and ongoing TD. Travel destinations were grouped into
nine regions as modified from the United Nations classification, in line
with our previous study [24] (Table 1).
Study participants were divided into four groups by the presence or
absence of TD and antibiotic use (AB) during travel: 1) no TD and no
antibiotic use (TD–AB–), 2) no TD but antibiotics taken during travel
(TD–AB+), 3) TD during travel but no antibiotic use (TD+AB–), and 4)
TD and antibiotic use during travel (TD+AB+). Since doxycycline as
an antimalarial is taken throughout a journey, and is thus not expected
to cause a sudden temporary impact on gut microbiota while abroad, we
chose to include doxycycline users in the AB– group if no other
antibiotics had been taken. The same approach has been used in studies
assessing the impact of antibiotic use on risk of acquiring ESBL-PE
[7,8].
2.3. Collection and laboratory analysis of stool samples
Collection and handling of the stool samples and the multiplex qPCR
method have been described previously [29]. In short, after returning
home, the travellers provided a post-travel sample from the first (or
second) stools. The faecal samples were collected as swabs in Copan
M40 Transystem tubes (Copan Diagnostics, Brescia, Italy) and mailed to
the laboratory. Once arrived (within one to three days after sampling),
total nucleid acids were extracted using the standard semi-automated
protocol of easyMAG (bioMérieux, Marcy-l’Etoile, France). The analyses
were carried out with a multiplex qPCR method that covers the fol-
lowing pathogens: diarrhoeagenic E. coli including enteroaggregative
(EAEC), enteropathogenic (EPEC), enterotoxigenic (ETEC), en-
terohaemorrhagic (EHEC) and enteroinvasive (EIEC) E. coli or Shigella
as well as Salmonella, Yersinia, Vibrio cholerae and Campylobacter coli/
jejuni.
2.4. Statistical analysis
Statistical analyses were carried out with SPSS 22 (IBM Corp,
Armonk, NY).
The chi-square test or Fisher's exact test were used to compare ca-
tegorical variables when applicable. Binomial regression model was
used to obtain profile likelihood confidence intervals for the propor-
tions of the various pathogens in geographical regions or, in cases
where computation did not converge, asymptotic Wald confidence in-
tervals were used. The possible differences in the effect of antibiotics on
pathogen findings (those associated with TD in our previous study: any
pathogen, EPEC, EAEC, ETEC or Campylobacter [15]) was compared in
the five most popular regions with binomial logistic regression analysis
(interaction between antibiotic and region). Statistical significance was
determined as either 95% confidence intervals not overlapping, or
ranging only either above or below 1.
Fig. 1. Study protocol for investigating bacterial pathogen findings among Finnish travellers with respect to occurrence of TD and use of antibiotics.
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3. Results
3.1. Traveller characteristics and use of antibiotics
The background data for the 456 travellers are provided in Table 1.
In total, 74 travellers (16%) reported antibiotic use during journey;
89% (66/74) of them had taken antibiotics for TD. Of these regimens,
50 (76%) were fluoroquinolones and eleven (17%) macrolides. The
probability of taking antibiotics for TD was found similar across the
various geographical regions (p=0.737).
Of travellers with TD, 21% (66/313) took antibiotics, whereas
among the asymptomatic, antibiotic use was reported by 6% (8/143).
Symptoms were still ongoing at return among 47% (115/247) of those
in group TD+AB- and 42% (28/66) in group TD+AB+ (p = 0.549).
3.2. Bacterial pathogen findings among travellers having used antibiotics
Bacterial pathogens were found in a total of 49% of the post-travel
stool samples from antibiotic users (Table 2); 19% (n= 14) had two or
more types of pathogens (14/36; 39% of those with a pathogen
finding). EAEC (20; 27%), EPEC (17; 23%) and ETEC (11; 15%) were
the most frequent findings, followed by Campylobacter (3; 4%), Shigella/
EIEC (3; 4%), EHEC (2; 3%) and Salmonella (2; 3%). No Vibrio cholerae
or Yersinia were detected.
In the whole group of 456 travellers, antibiotic use was associated
with fewer findings of any pathogen, multiple pathogens, EPEC or
EAEC, but more frequent cases of Shigella/EIEC. Doxycycline as an
antimalarial had no impact on pathogen findings.
3.3. Comparisons of findings among travellers with TD and with and
without use of antibiotics
Among those with TD, the proportion of pathogen-positive stool
samples was found lower among antibiotic users than non-users (33/66;
50% versus 205/247; 83%) (Table 2.). The difference was statistically
significant also for EPEC (15/66; 23% versus 117/247; 47%) and EAEC
(18/66; 27% versus 133/247; 54%), but not ETEC (11/66; 17% versus
64/247; 26%), Campylobacter (3/66; 5% versus 25/247; 10%) or other
pathogens.
Of the 50 travellers reporting use of fluoroquinolones,
Campylobacter was detected in the stools from three (6%); the propor-
tion was practically the same (7%) among those having not taken an-
tibiotics. Among those having used macrolides (n= 11), no
Campylobacter was found.
3.4. Differences in impact of antibiotics on pathogen findings across
geographical regions
There was no significant interaction between antibiotic use and
region with regard to any of the pathogens (Table 3.).
4. Discussion
Despite antimicrobial medications earlier being the mainstay of TD
treatment, few are the studies that report post-travel findings related to
taking them. Our results show antibiotic use to be associated with a
lower proportion of pathogen-positive stool samples – AB users 50%
versus non-users 83% – yet even among the users bacterial pathogens
were seen in half of the samples after return.
4.1. High rates of pathogens after antibiotic use
Pathogen findings despite antibiotic treatment may reflect not only
acquisition during continuing exposure afterwards but also the patho-
gens not being affected by the drugs taken, due to either initial re-
sistance or one developed over the course. In fact, new resistant pa-
thogens can even be favoured during antibiotic use because of selection
pressure and decreasing colonisation resistance. Indeed, we have re-
cently showed that fluoroquinolone users are prone to contract ESBL-PE
strains resistant to fluoroquinolone antibiotics [27].
4.2. Antibiotic use reduced findings with EAEC and EPEC but not with ETEC
As expected, among those with TD, the proportion of pathogen-
positive stool samples proved lower for antibiotic users than non-users
(50% vs. 83%). This finding contrasts the results of Gascon et al. [23],
who explored returning travellers with TD: prior antibiotic use did not
influence the proportion of pathogens in this group. The study does not
report findings with individual pathogens [23]. In our study, antibiotic
use reduced the findings with EAEC (23% vs. 47%) and EPEC (27% vs.
54%), but not other individual pathogens (Table 2.). The results accord
with those reported by Schultz et al. [1] who found EAEC and diffusely
adherent E. coli but not ETEC in reduced proportions, if returning tra-
vellers had taken antibiotics while abroad. The resistance rates for
ETEC, and EAEC have increased over the years [30,31]; research into
the resistance for EPEC is scarce. We believe that the smaller impact of
antibiotic use on ETEC rates rather reflects this pathogens' relatively
fast disappearance from the stools. In our previous report on travellers
not having used antimicrobials [16] ETEC was identified at lower rates
among travellers with resolved (22/132; 17%) than ongoing TD
Table 1
Characteristics of 456 Finnish travellers with or without TD (TD+ and TD–) and using or not using antibiotics (AB+ and AB–).a
AB+/–TD+/– Total
AB–TD–N (%) AB–TD+N (%) AB+TD–N (%) AB+TD+ N (%) N (%)
Ongoing TD symptoms 0 115 (47) 0 28 (42) 143 (46)
Age (years) median 46 (IQR 30–60) 33 (IQR 27–50) 27.5 (IQR 23–60.25) 32.5 (IQR 28–56.75) 36 (IQR 27–54.25)
Male 54 (40) 95 (38) 4 (50) 21 (32) 174 (38)
Female 81 (60) 152 (62) 4 (50) 45 (68) 282 (62)
Duration of travel (days), median 15 (IQR 10–18) 17 (IQR 14–28.25) 34 (IQR 12.75–75) 26 (IQR 16–39.5) 16 (IQR 13–27)
South Asia 12 (9) 40 (16) 2 (25) 15 (23) 69 (15)
Southeast Asia 23 (17) 68 (28) 1 (13) 15 (23) 107 (23)
South and Central America and the Caribbean 16 (12) 20 (8) 0 (0) 4 (6) 40 (9)
Europe, Australia, North America 13 (10) 3 (1) 1 (13) 0 (0) 17 (4)
East Asia 3 (2) 2 (1) 0 (0) 2 (3) 7 (2)
Northern Africa and Middle East 7 (5) 4 (2) 0 (0) 1 (2) 12 (3)
Southern Africa 11 (8) 10 (4) 1 (13) 2 (3) 24 (5)
Western and Middle Africa 25 (19) 43 (17) 3 (38) 13 (20) 84 (18)
Eastern Africa 25 (19) 57 (23) 0 (0) 14 (21) 96 (21)
Total (% of all travellers) 135 (30) 247 (54) 8 (2) 66 (15) 456 (100)
a Doxycycline as continuing antimalarial included in AB– if no other antibiotic was used.
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symptoms (42/115; 37%; OR:2.9:95% CI:1.6–5.2); the same did not
appear to apply to EAEC.
Interestingly, the impact of antibiotic treatment on pathogen de-
tection rates did not differ between the various geographical regions
(Table 3), suggesting that differences in resistance do not account for
the findings after antibiotic use, at least not entirely.
4.3. Shigella/EIEC more common after antibiotic use
It is noteworthy that during travel Shigella/EIEC was seen more
frequently among antibiotic users than non-users. Even though the
proportion of travellers carrying Shigella/EIEC remained small, this
finding could reflect antibiotics disrupting colonisation resistance, thus
facilitating colonisation and infection with pathogenic bacteria. Indeed,
antimicrobial treatment has been found to be associated with increased
risk of contracting Salmonella [32,33] and any bacteria resistant to the
antibiotic administered [27]; we are not aware of any similar reports
concerning Shigella/EIEC.
4.4. Campylobacter not found after macrolide use
The finding that Campylobacter was detected among travellers
having used fluoroquinolones but not among those who had taken
macrolides accords with the commonness of fluoroquinolone resistance
among Campylobacter strains particularly in South and Southeast Asia
[34], where the majority of our cases with Campylobacter had visited
[24]; strains from these geographical regions are still mostly sensitive to
macrolides [34]. In line with our results, prior treatment with FQ but
not macrolide antibiotics has been shown to be connected with Cam-
pylobacter findings [35]. However, Campylobacter eradication rates have
not been associated with clinical cure [18,21]. Interestingly, among our
travellers, the clinical picture of TD was similar for macrolide (4/9;
44% severe TD) and fluoroquinolone (21/48; 44% severe TD) users.
4.5. Doxycycline as antimalarial has no impact on pathogen findings
When taken as an antimalarial during the journey, no effect was
seen of doxycycline on pathogen findings. This was expected, since
doxycycline is no longer considered a valid drug for intestinal patho-
gens [13,30] nor in prevention of TD [13,36]. Moreover, in one study
[36], doxycycline as an antimalarial did not influence the pathogen
findings among travellers with TD; those remaining asymptomatic were
not included in the analyses.
4.6. Considerations of antibiotic use for TD
Liberal use of antibiotics for TD has been justified by the disruption
to travel plans caused by TD [13]. In addition, theoretic preventive
effect on post-TD sequelae such as IBS has been suggested [13]. How-
ever, the relationship between common TD pathogens and IBS is not
clear: in the study by Nair et al. only LT-ETEC and Providencia spp. were
associated with post-travel functional abdominal symptoms; none of the
pathogens analysed related to IBS [37]; they did not report possible
antibiotic use. Moreover, in two large prospective traveller studies
[5,9], and in one randomised trial [38], antimicrobials had no effect on
the risk of post-travel IBS. Contrariwise, some investigations have
shown that taking them for TD or infectious diarrhoea rather increases
the risk of IBS [39,40]. Pathogens found in stools after antibiotic
treatment, as seen in our research, may partly explain why antibiotics
used to treat TD have not reduced the risk of IBS.
The proportion of travellers with symptoms still ongoing at return
was similar between TD+AB– (47%) and TD+AB+ (42%) groups. The
lack of difference may be explained by 32% of the volunteers (data not
shown) having taken, instead of antibiotics, loperamide, a drug effec-
tive for TD [41] which does not predispose to acquisition of multidrug-
resistant bacteria [26]. Actually, in our recent review, we found no
studies comparing the efficacy of loperamide to current antibiotics
taken singly for TD, but it is evident that both are efficacious in treating
the disease [41].
4.7. Implications for further research
When assessing the role of various aetiological agents in TD, a
number of investigations have overlooked the possible use of antibiotics
Table 3
Findings with any pathogen, EPEC, EAEC, ETEC and Campylobacter in relation to the use of antibiotics (AB) in five geographical subregions: South Asia, Southeast
Asia, West and Central Africa, East Africa, and South and Central America, and the Caribbean.
All Any pathogen EPEC EAEC ETEC Campylobacter
n (%) n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) N % (95% CI)
South Asia
Total 69 (15) 54 78 (69–88)* 37 54 (42–66) 39 57 (45–69) 15 22 (12–32) 12 17 (8–27)
AB− 52 (75) 45 87 (77–96)* 29 56 (42–69) 32 62 (48–74) 12 23 (13–36) 10 19 (10–31)
AB+ 17 (25) 9 53 (29–77)* 8 47 (25–70) 7 41 (20–65) 3 18 (5–40) 2 12 (2–32)
Southeast Asia
Total 108 (26) 74 69 (60–77)* 44 41 (31–50) 34 31 (23–41) 20 19 (11–26) 13 12 (6–18)
AB− 91 (84) 65 71 (62–80) 42 46 (36–56) 30 33 (24–43) 18 20 (13–29) 11 12 (6–20)
AB+ 16 (16) 8 50 (27–73) 2 13 (2–34) 3 19 (5–42) 1 6 (0–25) 1 6 (0–25)
West and Central Africa
Total 85 (19) 60 71 (61–80)* 36 42 (32–53) 39 46 (35–57) 14 16 (8–25) 1 1 (0–3)*
AB− 68 (80) 51 75 (64–84) 31 46 (34–57) 34 50 (38–62) 11 16 (9–26) 0 0
AB+ 16 (20) 8 50 (27–73) 4 25 (9–49) 5 31 (13–56) 3 19 (5–42) 0 0
East Africa
Total 96 (21) 80 83 (76–91)* 45 47 (37–57) 50 52 (42–62) 32 33 (24–43) 5 5 (1–10)
AB− 82 (85) 71 87 (79–94)* 44 54 (43–64) 45 55 (44–65) 28 34 (25–45) 5 6 (2–13)
AB+ 14 (15) 9 64 (39–89)* 1 7 (0–28) 5 36 (15–62) 4 29 (10–54) 0 0
South and Central America and Caribbean
Total 40 31 78 (65–90)* 17 43 (26–59) 15 38 (22–53) 4 10 (0–20) 0 0
AB− 36 (90) 30 83 (69–93) 20 56 (39–72)* 15 42 (27–58) 4 11 (4–24) 0 0
AB+ 4 (10) 1 25 (0–67)* 3 75 (33–100)* 0 0 0 0 0 0
Statistical analysis on difference between regions (interaction AB*region)
P-value for difference in effect of AB 0.664 0.290 1.000 0.854 1.000
95% confidence intervals are profile likelihood confidence intervals except when computation did not converge and confidence intervals were calculated using
asymptotic Wald formula (marked with *).
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earlier during the journey [14,15], while some others have excluded
from their analyses participants who had taken antibiotics three to
seven days prior to stool sampling [17,19,21,22,42]. This interval ap-
pears too short, since intestinal microbiota have been shown to be af-
fected by antimicrobials for up to twelve months [43]. If stools are
analysed shortly after antibiotic treatment from samples collected while
abroad [17–22,44], the results fail to represent the ’final’ pathogen
findings on travellers' return to better hygienic conditions at home. Our
data show that the specimens of those having used antimicrobials
should be examined separately, but not omitted from studies analysing
the prevalence of various pathogens.
4.8. Limitations
The principal limitation of our study was not having available the
exact start or end dates of antibiotic treatment, which made it im-
possible to assess the duration of the effect of antibiotics on pathogen
findings and the time the travellers were exposed to new pathogens
during/after the course; we had only recorded the presence/absence of
symptoms at return. Changes in the intestinal microbiota have, how-
ever, been described to persist for even a year [43]. Molecular diag-
nostic methods have been criticized for oversensitivity in detecting
pathogens [45,46], yet also studies applying culture-based methods
have detected bacterial pathogens in up to 33% of stools after use of
antibiotics [19,21,22]. Moreover, it is unlikely that free nucleic acids
could resist active DNAses in the intestinal environment and qPCR
methods would thus measure non-viable bacteria [47,48]. Since diar-
rhoeagenic E. coli were not cultured, we have no data on the suscept-
ibility profiles.
5. Conclusion
Bacterial pathogens were found in stools from half of travellers
using antibiotics for diarrhoea. It appears that either the pathogens
have initially been resistant to the drug taken or the individuals have
contracted other, potentially resistant bacteria during or soon after the
intake abroad, while still under exposure. Treatment of TD with anti-
biotics while abroad should not be interpreted to indicate pathogen
eradication.
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